Skip to main content
TipRanks
Go Ultimate75% OFF

Kymera Therapeutics (KYMR) Stock Statistics & Valuation Metrics

454 Followers

Total Valuation

Kymera Therapeutics has a market cap or net worth of $10.89B. The enterprise value is $10.30B.

Market Cap
$10.89B
Enterprise Value
$10.30B

Share Statistics

Kymera Therapeutics has 85,371,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
85,371,400
Owned by Insiders
11.65%
Owned by Institutions
73.24%

Financial Efficiency

Kymera Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.88%.

Return on Equity (ROE)
-0.20
Return on Assets (ROA)
-0.18
Return on Invested Capital (ROIC)
-20.88%
Return on Capital Employed (ROCE)
-0.21
Revenue Per Employee
143.59K
Profits Per Employee
-1.14M
Employee Count
273
Asset Turnover
0.02
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Kymera Therapeutics is -35.14. Kymera Therapeutics’s PEG ratio is 10.20.

PE Ratio
-35.14
PS Ratio
106.54
PB Ratio
7.91
Price to FCF
-37.70
Price to Operating Cash Flow
-44.41
PEG Ratio
10.20

Income Statement

In the last 12 months, Kymera Therapeutics had revenue of 39.20M and earned -311.40M in profits. Earnings per share was -3.69.

Revenue
39.20M
Gross Profit
39.20M
Operating Income
-349.40M
Pretax Income
-311.62M
Net Income
-311.40M
EBITDA
-303.06M
Earnings Per Share (EPS)
-3.69

Cash Flow

In the last 12 months, operating cash flow was -287.56M and capital expenditures -1.33M, giving a free cash flow of -288.89M billion.

Operating Cash Flow
-287.56M
Free Cash Flow
-288.89M
Free Cash Flow per Share
-2.89

Dividends & Yields

Kymera Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-2.69%
Earnings Yield
-2.78%

Stock Price Statistics

Beta
1.71
52-Week Price Change
100.49%
50-Day Moving Average
117.13
200-Day Moving Average
99.92
Relative Strength Index (RSI)
54.88
Average Volume (3m)
834.16K

Important Dates

Kymera Therapeutics upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Feb 25, 2027
Ex-Dividend Date
―

Financial Position

Kymera Therapeutics as a current ratio of 10.47, with Debt / Equity ratio of 5.21%

Current Ratio
10.47
Quick Ratio
10.47
Debt to Market Cap
0.00
Net Debt to EBITDA
0.91
Interest Coverage Ratio
-1403.21

Taxes

In the past 12 months, Kymera Therapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Kymera Therapeutics EV to EBITDA ratio is -30.58, with an EV/FCF ratio of -36.13.

EV to Sales
102.11
EV to EBITDA
-30.58
EV to Free Cash Flow
-36.13
EV to Operating Cash Flow
-36.30

Balance Sheet

Kymera Therapeutics has $971.21M in cash and marketable securities with $76.60M in debt, giving a net cash position of $894.62M billion.

Cash & Marketable Securities
$971.21M
Total Debt
$76.60M
Net Cash
$894.62M
Net Cash Per Share
$10.48
Tangible Book Value Per Share
$16.13

Margins

Gross margin is 174.52%, with operating margin of -396.08%, and net profit margin of -341.87%.

Gross Margin
174.52%
Operating Margin
-396.08%
Pretax Margin
-342.09%
Net Profit Margin
-341.87%
EBITDA Margin
-333.89%
EBIT Margin
-341.82%

Analyst Forecast

The average price target for Kymera Therapeutics is $147.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$147.67
Price Target Upside
15.75% Upside
Analyst Consensus
Strong Buy
Analyst Count
15
Revenue Growth Forecast
133.77%
EPS Growth Forecast
-0.64%

Scores

Smart Score
7
AI Score
60